Author/Authors :
Yiğiter, R Gaziantep Üniversitesi - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey , Elçi, M A Gaziantep Üniversitesi , - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey , Akçalı, A Gaziantep Üniversitesi - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey , Altunışık, E Gaziantep Üniversitesi - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey , Demir, F Gaziantep Üniversitesi - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey , Neyal, M Gaziantep Üniversitesi - Tıp Fakültesi - Nöroloji Anabilim Dalı, Turkey
Abstract :
Wilson s disease is an autosomal recessive disease seen in later childhood or young adulthood which is caused by an accumulation of copper in tissues which leads to hepatic, neurological, psychiatric symptoms or a combination of these. A copper chelator agent called D-penicillamine, which is being widely used with other drugs for Wilson s disease, increases copper excretion in urine. Myasthenia gravis is an autoimmune disorder of the neuromuscular junction causing muscle weakness and fatigue. It is known that some drugs such as D-penicillamine can effect the neuromuscular junction and worsen the clinical results of patients. D-penicillamine was given to an 18-year-old female patient with Wilson s disease. The patient was admitted to our clinic with complaints of generalized weakness for three months and after the physical examination and laboratory findings we diagnosed her as having myasthenia gravis secondary to drugs. We have found it significant to present the case that some medicines used in clinical diseases may cause another clinical case. And if an unexpected clinical process develops, the medicines in use may need to be reconsidered.
NaturalLanguageKeyword :
Wilson s disease , myasthenia gravis , D , penicillamine
